GlassScriptPhysician profile
Marilyn E Roberts
NPI 1033576525
$985.44
in general payments reported to CMS, 2019-2025
19 companies · $586 in 2025
The $586 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.37 · 2022: $46.23 · 2023: $12.97 · 2024: $292 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $233.15 | 2023-2025 | |
| Novo Nordisk INC | $108.99 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $96.46 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $76.24 | 2024-2025 | |
| Exact Sciences Corporation | $56.25 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $55.28 | 2025 | Mounjaro, Zepbound, Jardiance |
| Edwards Lifesciences Corporation | $54.72 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $51.49 | 2024-2025 | Gemtesa |
| Abbott Laboratories | $42.45 | 2025 | Freestyle Libre 3 |
| Collegium Pharmaceutical, INC. | $34.46 | 2025 | Jornay Pm |
| Biomarin Pharmaceutical INC. | $23.60 | 2024 | Voxzogo 1.2mg |
| Alvogen INC | $23.14 | 2025 | Teriparatide |
| Ironshore Pharmaceuticals INC. | $22.47 | 2024 | |
| Sanofi Pasteur INC. | $20.71 | 2024 | |
| Biogen, INC. | $19.74 | 2024 | Skyclarys |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.50 | 2024 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.45 | 2025 | Xifaxan |
| Antares Pharma, INC. | $15.99 | 2025 | Xyosted |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.35 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilyn Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.